

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2017 OS

DESPATCHED ON 23 MAY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B7, B8; Cw7, Cw-; DR4, DR15; DQ6, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				15	14	14	15	28	32	32	32	28	30	30	29	
				13	5	6	0	24	1	0	0	23	30	26	1	
				2	9	8	15	4	31	32	32	5	0	4	28	
				0	1	1	0	10	6	6	6	11	9	9	10	
				86.7%	35.7%	42.9%	0.0%	85.7%	3.1%	0.0%	0.0%	82.1%	100.0%	86.7%	3.4%	
				13.3%	64.3%	57.1%	100.0%	14.3%	96.9%	100.0%	100.0%	17.9%	0.0%	13.3%	96.6%	
Consensus				Positive	Not Assessed	Not Assessed	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
HLA Antibody Specificity (Defined By CDC)				A3	DR5 DR6 DQ6	DQ3	A32 B44 DR7	A3	DR5 DR6 DQ6	DQ3	A32 B44 DR7	A3	DR5 DR6 DQ6	DQ3	A32 B44 DR7	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101		YES	YES	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
112	YES			Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Cell treated with Percoll 40%
114		YES	YES	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Not tested as samples were not received by laboratory
116	YES	YES	YES	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
119	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
120		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
128	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
133		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
139	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
143		YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
145	YES	YES	YES	Positive	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Equivocal	Positive	Positive	Negative	Unable to test class II/B cells. 1 = negative 2 = equivocal 4 = weak 8 = strong NT. Due to holidays in France (day of the ascent) and kidney pre transplant cross match in emergencies we could not test cytotoxic crossmatching scheme 2A with 2A05 and 2A06 samples before the 26th may. Samples were kept at 4°C but it is known to decrease HLA expression and sensitivity of the CDC. It is an unauthorized practice in our Lab. Impossible to perform CDC test due to recall of Class II Dynabeads from ThermoFisher. We did not have a replacement reagent available.
147	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
154	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
				Positive	Positive	Positive	Negative	NT	NT	NT	NT	NT	NT	NT	NT	
157		YES	YES	Positive	Negative	Negative	Negative	NT	NT	NT	NT	NT	NT	NT	NT	
159	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
162	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
163	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
169	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
181	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
186	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
189	YES			Negative	Positive	Positive	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	B cells NT due to use of Dynabeads HLA class II catalog number: 21003, Lot number: 00461955.
190	YES	YES	YES	Positive	Equivocal	Equivocal	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
193	YES	YES	YES	Positive	Equivocal	Equivocal	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
194	YES	YES	YES	Positive	Equivocal	Equivocal	Negative	Equivocal	Negative	Negative	Negative	Equivocal	Positive	Positive	Negative	No B cells found in samples
195	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
197	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
204	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
206	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
209	YES	YES	YES	Negative	Negative	Positive	Negative	Equivocal	Negative	Negative	Negative	NT	NT	NT	NT	Dynabead issue In the Scheme 2A cytotoxic crossmatching study, the PBL portion was previously mistakenly marked. For this reason, I would like you to make the evaluation on T and B cell basis.
216	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
223	YES	YES	YES	Positive	Negative	Negative	Negative	NT	NT	NT	NT	NT	NT	NT	NT	Samples were not tested due to national holiday
227	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	
229	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	Technical failure
232	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	
235	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	
238	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
239	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Negative	Positive	Negative	Negative	
245	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
252	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
259	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
260		YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
262				Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
268		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Low viability on B cells
284		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
292	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	Low viability on B cells due to problem with new lot of class II immunomagnetics beads (one lambda).
293	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
294	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Samples were received on 26th May instead of 25th May, morphology and viability of cells very poor therefore samples were NT.
297	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
321	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	Results on T cell with DTT are uninterpretable
351	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
				NT	Negative	Negative	Negative	NT	Negative	Negative	Negative	NT	Positive	Positive	Negative	Cell viability too low to perform tests
				NT	Negative	Negative	Negative	NT	Negative	Negative	Negative	NT	Positive	Positive	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A05/2017 OS

DESPATCHED ON 23 MAY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	1	6	4	1	90		
112	8	1	4	2											
114					2	1	1	1	2	8	8	2			
116															
119	8	1	1	1									90		
120					8	1	1	1	8	8	8	1		100	100
128	4	1	1	1	1								98		
133					8	2	2	2	8	8	8	2	95	100	95
139	6	1	1	1	6	1	1	1	8	8	8	1	85	85	85
143					1	1	1	1	NT	NT	NT	NT		93.8	
145										8	8			100	80
147	8	4	4	1	8	1	1	1	8	8	8	1	100	100	100
154															
157															
159					8	1	1	1	8	8	8	1		99	99
162					8				8	8	8			100	100
163					8	1	1	1	6	8	8	1		80	80
169					8	1	1	1	8	8	8	1		98	98
181					8	2	1	1	8	8	8	2	100	100	100
186					6	0	0	0	0	8	6	0		99	99
189	1	6	6	1											
190					20%	1%	1%	1%						99	80
193	8	2	2	1	8	1	1	1	8	8	8	1	95	95	95
194															
195					8	1	1	1							
197					Strong				Strong				100	95	95
204					6	1	2	1	8	8	8	1		100	95
206					4	0	0	0	8	8	8	0		100	80
209	1	1	4	1	NT	NT	NT	NT	NT	NT	NT	NT	80		
216	4	1	1	1									95		
223															
227					8				8	8	8			98	98
229															
232	80%	0%	0%	0%									80%		
235	8	1	2	1									85		
238	8	4	4	1	8	1	1	1	6	8	8	4	95	95	80
239	6	6	1	1	6	6	1	1	1	8	1	1	90	90	90
245	2	2	2	1	2	1	1	1	2	8	8	1	100	100	100
252	6	2	2	2					6	6	2-4	2	80		70
259															
260															
262													100	100	100
268					8	1	1	1	2	4	1	1		96	70
284					8	1	1	1	6	8	8	1		95	30
292					6	1	1	1	8	8	8	1		85	60
293													10	10	5
294					6	0	0	0	6	8	8	0		95	95
297					6	1	1	1	6	8	8	1	80	80	80
321						1	1	1	8	8	8	1		95	95
351															

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2017 OS

DESPATCHED ON 23 MAY 2017

HLA PHENOTYPE OF BLOOD DONOR: HLA-A1, A3; B7, B8; Cw7, Cw-; DR4, DR15; DQ6, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				13	12	12	13	27	30	30	30	27	28	28	27	
				10	4	6	0	22	0	0	0	22	27	24	2	
				3	8	6	13	5	30	30	30	5	1	4	25	
				0	1	1	0	7	4	4	4	9	8	8	9	
				76.9%	33.3%	50.0%	0.0%	81.5%	0.0%	0.0%	0.0%	81.5%	96.4%	85.7%	7.4%	
				23.1%	66.7%	50.0%	100.0%	18.5%	100.0%	100.0%	100.0%	18.5%	3.6%	14.3%	92.6%	
				Consensus												
				Positive	Not Assessed	Not Assessed	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
				A3	DR5 DR6 DQ6	DQ3	A32 B44 DR7	A3	DR5 DR6 DQ6	DQ3	A32 B44 DR7	A3	DR5 DR6 DQ6	DQ3	A32 B44 DR7	
HLA Antibody Specificity (Defined By CDC)																
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
112	YES			Positive	Negative	Positive	Negative									Cell treated with Percoll 40%
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
116		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Not tested as samples were not received by laboratory
119	YES			Negative	Negative	Negative	Negative									
120		YES	YES					Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
128																
133		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
139	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
143		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
145								Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
147	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	Unable to test class II/B cells. 1 = negative 2 = equivocal 4 = weak 8 = strong
154																
157			YES									NT	NT	NT	NT	Impossible to perform CDC test due to recall of Class II Dynabeads from ThermoFisher. We did not have a replacement reagent available.
159		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
162		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
163		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
169		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
181		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
186		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Positive	Positive	Negative	
189	YES			Negative	Positive	Positive	Negative									
190		YES	YES	NT				NT	Negative	Negative	Negative	NT	NT	NT	NT	
193	YES	YES	YES	Positive	Equivocal	Equivocal	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	B cells NT due to use of Dynabeads HLA class II catalog number: 21003, Lot number: 00461955.
194		YES	YES					Equivocal	Negative	Negative	Negative	Equivocal	Positive	Positive	Negative	
195		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	No B cells found in samples
197		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
204		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
206		YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
209	YES			Negative	Negative	Positive	Negative					Negative	NT	NT	NT	Dynabead issue
216	YES			Positive	Negative	Negative	Negative									In the Scheme 2A cytotoxic crossmatching study, the PBL portion was previously mistakenly marked. For this reason, I would like you to make the evaluation on T and B cell basis. Samples were not tested due to national holiday
223																Technical failure
227		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	NT	
229	YES															
232																
235	YES			Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Positive	
238	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
239																
245	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
252	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
259																
260		YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
262		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
268		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	Low viability on B cells
284		YES	YES													Low viability on B cells due to problem with new lot of class II immunomagnetics beads (one lambda).
292		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
293		YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Samples were received on 26th May instead of 25th May, morphology and viability of cells very poor therefore samples were NT.
294		YES	YES													Results on T cell with DTT are uninterpretable
297		YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
321		YES	YES	NT	Negative	Negative	Negative	NT	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
351		YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Cell viability too low to perform tests

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A05/2017 OS

DESPATCHED ON 23 MAY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					1	1	1	1	1	9	6	1	90		
112	8	1	4	2											
114															
116															
119	1	1	1	1									90		
120					8	1	1	1	8	8	8	1	100	100	
128													98		
133					8%	2%	2%	2%	8%	8%	8%	2%	95	100	95
139	6	1	1	1	6	1	1	1	8	8	8	1	85	85	85
143					1	1	1	1	NT	NT	NT	NT		93.8	
145														100	80
147	8	4	4	1	8	1	1	1	NT	NT	NT	NT	100	100	100
154															
157															
159					8%	1%	1	1	8%	8%	8	1		99	99
162					8				8	8	8			100	100
163					8	1	1	1	6	8	8	1		80	80
169					6	1	1	1	8	8	8	1		98	98
181					8	2	1	1	8	8	8	2	100	100	100
186					6	0	0	0	0	6	6	0		99	99
189	1	6	6	1											
190						1%	1%	1%						99	80
193	8	2	2	1	8	1	1	1	8	8	8	1	95	95	96
194															
195					8	1	1	1						>95	
197					Strong				Strong				100	95	95
204					6	1	2	1	8	8	8	1		100	95
206					0	0	0	0	0	0	0	0		100	80
209	1	1	4	1	NT	NT	NT	NT	NT	NT	NT	NT	80		
216	4	1	1	1									95		
223															
227					8				8	8	8			98	98
229															
232													80%		
235	8	1	1	1									85		
238	8	4	4	1	8	1	1	1	6	8	8	4	95	95	80
239													90	90	90
245	2	2	2	1	2	1	1	1	2	8	8	1	100	100	100
252	6	2	2	2					6	6	2-4	2	80		70
259															
260															
262	4	1	1	1	4	1	1	1	4	6	8	8	100	100	100
268					8	1	1	1	2	4	1	1		96	70
284					8	1	1	1	8	8	8	1		95	30
292					6	1	1	1	8	8	8	1		85	60
293													10	10	5
294														95	95
297					8	1	1	1	8	8	8	1	80	80	80
321						1	1	1	8	8	8	1		95	95
351															